Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Jun 15;18(8):e30913.
doi: 10.5812/ircmj.30913. eCollection 2016 Aug.

Case Report of a Patient Undergoing Peritoneal Dialysis with Encapsulating Peritoneal Sclerosis Superimposed With Calciphylaxis

Jun Li Tsai  1 , Ming Ju Wu  2 , Cheng Hsu Chen  2 , Shang Feng Tsai  3
Affiliations
Case Reports

Case Report of a Patient Undergoing Peritoneal Dialysis with Encapsulating Peritoneal Sclerosis Superimposed With Calciphylaxis

Jun Li Tsai et al. Iran Red Crescent Med J. .

Abstract

Introduction: Encapsulating peritoneal sclerosis (EPS) is a rare but devastating complication of peritoneal dialysis (PD). Tamoxifen has been generally well-tolerated, even without randomized controlled trials.

Case presentation: Herein, we report a case of a patient undergoing 12 years of PD who developed EPS and calciphylaxis simultaneously. We also provide a comprehensive discussion about the association between EPS and calciphylaxis. Moreover, although tamoxifen is used in EPS due to its inhibition of fibroblast-transforming growth factor beta (TGFβ) production, it may worsen the calciphylaxis due to a hypercoagulable state.

Conclusions: We suggest avoiding the use of tamoxifen for EPS in patients with superimposed calciphylaxis.

Keywords: Calciphylaxis; Encapsulating Peritoneal Sclerosis; Tamoxifen.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:We do not have any relationships with pharmaceutical companies or other entities, such as employment contracts, consultancy, advisory boards, speaker bureaus, membership on boards of directors, or stock ownership that could be perceived to represent a financial conflict of interest.

Figures

Figure 1.
Figure 1.. A, KUB x-ray showing uremic arterial calcifications of the abdominal aorta with dilatation (arrowhead) and encapsulating peritoneal sclerosis in the wall of the small intestine (arrow); B, CT image showing calciphylaxis in the abdominal aorta (arrowhead); C, CT image showing diffuse thickening of the peritoneal wall of the small intestine
See this image and copyright information in PMC

References

    1. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000;20 Suppl 4:S43–55. - PubMed
    1. Oran E, Seyit H, Besleyici C, Unsal A, Alis H. Encapsulating peritoneal sclerosis as a late complication of peritoneal dialysis. Ann Med Surg (Lond). 2015;4(3):205–7. doi: 10.1016/j.amsu.2015.03.006. - DOI - PMC - PubMed
    1. Yavuz R, Akbulut S, Babur M, Demircan F. Intestinal Obstruction Due to Idiopathic Sclerosing Encapsulating Peritonitis: A Case Report. Iran Red Crescent Med J. 2015;17(5):e30913. doi: 10.5812/ircmj.17(5)2015.21934. - DOI - PMC - PubMed
    1. Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66(1):133–46. doi: 10.1053/j.ajkd.2015.01.034. - DOI - PMC - PubMed
    1. Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson EJ. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013;8(7):1162–70. doi: 10.2215/CJN.09880912. - DOI - PMC - PubMed

Publication types

LinkOut - more resources